CVD Logo
Calculator

|  About the Guideline and Calculator

References

1

  1. Pylypchuk R, Wells S, Kerr A, et al. Cardiovascular disease risk prediction equations in 400 000 primary care patients in New Zealand: a derivation and validation study. Lancet 2018; 391(10133):1897-1907. doi:10.1016/s0140-6736(18)30664-0
  2. Wells S, Riddell T, Kerr A, et al. Cohort Profile: The PREDICT Cardiovascular Disease Cohort in New Zealand Primary Care (PREDICT-CVD 19). Int J Epidemiol 2017; 46(1):22. doi:10.1093/ije/dyv312
  3. Australian Bureau of Statistics. Causes of Death, Australia (2021). Canberra: ABS; 2022 [updated 19/10/2022]; Available from:
    abs.gov.au
  4. Hajar R. Risk factors for coronary artery disease: historical perspectives. Heart Views 2017; 18(3):109-114. doi:10.4103/heartviews.Heartviews_106_17
  5. National Vascular Disease Prevention Alliance. Guidelines for the management of absolute cardiovascular disease risk: National Stroke Foundation; 2012.
  6. National Health and Medical Research Council. 2016 NHMRC standards for guidelines. NHMRC; 2016. Available from:
    nhmrc.gov.au
  7. Schünemann H, Brożek J, Guyatt G, et al., editors. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. Updated October 2013: GRADEpro; 2013.
  8. National Health and Medical Research Council. Policy on the disclosure of interests requirements for prospective and appointed NHMRC committee members. Canberra: NHMRC; 2019. Available from:
    nhmrc.gov.au
  9. National Health and Medical Research Council. Guidelines for guidelines handbook: NHMRC. Available from:
    nhmrc.gov.au
  10. Paige E, Welsh J, Zhang Y, et al. Updating Australia’s cardiovascular disease risk prediction equation: Evidence, methods and data for recalibration. Report for the National Heart Foundation of Australia: National Heart Foundation; 2022.
  11. Mehta S, Jackson R, Poppe K, et al. How do cardiovascular risk prediction equations developed among 30-74 year olds perform in older age groups? A validation study in 125 000 people aged 75-89 years. J Epidemiol Community Health 2020; 74(6):527-533. doi:10.1136/jech-2019-213466
  12. Banks E, Crouch SR, Korda RJ, et al. Absolute risk of cardiovascular disease events, and blood pressure- and lipid-lowering therapy in Australia. Med J Aust 2016; 204(8):320. doi:10.5694/mja15.01004
  13. Agostino JW, Wong D, Paige E, et al. Cardiovascular disease risk assessment for Aboriginal and Torres Strait Islander adults aged under 35 years: a consensus statement. Med J Aust 2020; 212(9):422-427. doi:10.5694/mja2.50529
  14. Calabria B, Korda RJ, Lovett RW, et al. Absolute cardiovascular disease risk and lipid-lowering therapy among Aboriginal and Torres Strait Islander Australians. Med J Aust 2018; 209(1):35-41. doi:10.5694/mja17.00897
  15. Australian Institute of Health and Welfare. Cardiovascular disease in women. Cat. no. CDK 15. Canberra: AIHW; 2019.
  16. McBride KF, Rolleston A, Grey C, et al. Māori, Pacific, Aboriginal and Torres Strait Islander women's cardiovascular health: where are the opportunities to make a real difference? Heart Lung Circ 2021; 30(1):52-58. doi:10.1016/j.hlc.2020.06.029
  17. Mehta S, Zhao J, Poppe K, et al. Cardiovascular preventive pharmacotherapy stratified by predicted cardiovascular risk: a national data linkage study. Eur J Prev Cardiol 2021. doi:10.1093/eurjpc/zwaa168
  18. Hyun KK, Redfern J, Patel A, et al. Gender inequalities in cardiovascular risk factor assessment and management in primary healthcare. Heart 2017; 103(7):492-498. doi:10.1136/heartjnl-2016-310216
  19. Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375(9731):2073-2081. doi:10.1016/s0140-6736(10)60674-5
  20. Modi ZJ, Lu Y, Ji N, et al. Risk of cardiovascular disease and mortality in young adults with end-stage renal disease: an analysis of the US renal data system. JAMA Cardiol 2019; 4(4):353-362. doi:10.1001/jamacardio.2019.0375
  21. Akioyamen LE, Genest J, Shan SD, et al. Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. BMJ Open 2017; 7(9):e016461. doi:10.1136/bmjopen-2017-016461
  22. Watts GF, Sullivan DR, Hare DL, et al. Integrated guidance for enhancing the care of familial hypercholesterolaemia in Australia. Heart Lung Circ 2021; 30(3):324-349. doi:10.1016/j.hlc.2020.09.943
  23. Pérez de Isla L, Alonso R, Mata N, et al. Predicting cardiovascular events in familial hypercholesterolemia: The SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study). Circulation 2017; 135(22):2133-2144. doi:10.1161/circulationaha.116.024541
  24. Paquette M, Bernard S, Cariou B, et al. Familial Hypercholesterolemia-Risk-Score: a new score predicting cardiovascular events and cardiovascular mortality in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2021; 41(10):2632-2640. doi:10.1161/atvbaha.121.316106
  25. Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375(9733):2215-2222. doi:10.1016/s0140-6736(10)60484-9
  26. Tancredi M, Rosengren A, Svensson AM, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med 2015; 373(18):1720-1732. doi:10.1056/NEJMoa1504347
  27. Rawshani A, Sattar N, Franzén S, et al. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. Lancet 2018; 392(10146):477-486. doi:10.1016/s0140-6736(18)31506-x
  28. van Staa TP, Gulliford M, Ng ES, et al. Prediction of cardiovascular risk using Framingham, ASSIGN and QRISK2: how well do they predict individual rather than population risk? PLoS One 2014; 9(10):e106455. doi:10.1371/journal.pone.0106455
  29. Pylypchuk R, Wells S, Kerr A, et al. Cardiovascular risk prediction in type 2 diabetes before and after widespread screening: a derivation and validation study. Lancet 2021; 397(10291):2264-2274. doi:10.1016/s0140-6736(21)00572-9
  30. Korda RJ, Soga K, Joshy G, et al. Socioeconomic variation in incidence of primary and secondary major cardiovascular disease events: an Australian population-based prospective cohort study. Int J Equity Health 2016; 15(1):189. doi:10.1186/s12939-016-0471-0
  31. Australian Bureau of Statistics. Socio-Economic Indexes for Areas. [Web page]: Australian Government; 2018 [cited 2021 December]; Available from:
    abs.gov.au
  32. Australian Government. Australian Aboriginal and Torres Strait Islander Health Plan 2013-2023. Canberra: Commonwealth of Australia; 2013. Available from:
    health.gov.au
  33. Lindbohm JV, Sipilä PN, Mars NJ, et al. 5-year versus risk-category-specific screening intervals for cardiovascular disease prevention: a cohort study. Lancet Public Health 2019; 4(4):e189-e199. doi:10.1016/s2468-2667(19)30023-4
  34. Bell KJ, Hayen A, Irwig L, et al. When to remeasure cardiovascular risk in untreated people at low and intermediate risk: observational study. BMJ 2013; 346:f1895. doi:10.1136/bmj.f1895
  35. National Aboriginal Community Controlled Health Organisation, The Royal Australian College of General Practitioners. National guide to a preventive health assessment for Aboriginal and Torres Strait Islander people. 3rd edn. East Melbourne: RACGP; 2018.
  36. Australian Institute of Health and Welfare. Better Cardiac Care measures for Aboriginal and Torres Strait Islander people: sixth national report 2021. Cat. no. IHW 263. Canberra: AIHW; 2021.
  37. Australian Institute of Health and Welfare. Australian Burden of Disease Study 2018: key findings: impact and causes of illness and death in Aboriginal and Torres Strait Islander people 2018. Australian Burden of Disease Study series no. 26. Cat. no. BOD 32. Canberra: AIHW; 2022. Available from:
    aihw.gov.au
  38. Ranthe MF, Petersen JA, Bundgaard H, et al. A detailed family history of myocardial infarction and risk of myocardial infarction – a nationwide cohort study. PLoS One 2015; 10(5):e0125896. doi:10.1371/journal.pone.0125896
  39. Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ 2017; 357:j2099. doi:10.1136/bmj.j2099
  40. Goff DC, Jr., Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129(25 Suppl 2):S49-73. doi:10.1161/01.cir.0000437741.48606.98
  41. Dhiman P, Kai J, Horsfall L, et al. Availability and quality of coronary heart disease family history in primary care medical records: implications for cardiovascular risk assessment. PLoS One 2014; 9(1):e81998. doi:10.1371/journal.pone.0081998
  42. Matsushita K, Jassal SK, Sang Y, et al. Incorporating kidney disease measures into cardiovascular risk prediction: Development and validation in 9 million adults from 72 datasets. EClinicalMedicine 2020; 27:100552. doi:10.1016/j.eclinm.2020.100552
  43. Kidney Health Australia. Chronic kidney disease (CKD) management in primary care. 4th edition. Melbourne, Australia: Kidney Health Australia; 2020. Available from:
    kidney.org.au
  44. Matsushita K, Coresh J, Sang Y, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol 2015; 3(7):514-525. doi:10.1016/s2213-8587(15)00040-6
  45. van der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int 2011; 79(12):1341-1352. doi:10.1038/ki.2010.536
  46. Australian Institute of Health and Welfare. Chronic kidney disease: Australian facts. Last updated: 23 Aug 2022 [Web report]: AIHW; 2022 [cited 2022 August]; Available from:
    aihw.org.au
  47. McDermott RA, McCulloch B, Li M. Glycaemia and albuminuria as predictors of coronary heart disease in Aboriginal and Torres Strait Islander adults: a north Queensland cohort. Med J Aust 2011; 194(10):514-518. doi:10.5694/j.1326-5377.2011.tb03087.x
  48. Wang Z, Hoy WE. Albuminuria and incident coronary heart disease in Australian Aboriginal people. Kidney Int 2005; 68(3):1289-1293. doi:10.1111/j.1523-1755.2005.00526.x
  49. Barr ELM, Barzi F, Rohit A, et al. Performance of cardiovascular risk prediction equations in Indigenous Australians. Heart 2020; 106(16):1252-1260. doi:10.1136/heartjnl-2019-315889

50

  1. Cunningham R, Poppe K, Peterson D, et al. Prediction of cardiovascular disease risk among people with severe mental illness: A cohort study. PLoS One 2019; 14(9):e0221521. doi:10.1371/journal.pone.0221521
  2. Malhi G, Bell E, Bassett D, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 2021 Jan;55(1):7-117. doi: 10.1177/0004867420979353
  3. Royal Australian and New Zealand College of Psychiatrists. Keeping body and mind together. Improving the physical health and life expectancy of people with serious mental illness: RANZCP; 2015. Available from:
    ranzcp.org
  4. PGalletly C, Castle D, Dark F, et al. Royal Australian and New Zealand College of psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry 2016; 50(5):410-472. doi:10.1177/0004867416641195
  5. Andrews G, Bell C, Boyce P, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of panic disorder, social anxiety disorder and generalised anxiety disorder. Aust N Z J Psychiatry 2018; 52(12):1109-1172. doi: 10.1177/0004867418799453
  6. Australian Bureau of Statistics. National Aboriginal and Torres Strait Islander Health Survey 2018-2019. [Web page] Canberra: Australian Bureau of Statistics; 2019; Available from:
    abs.gov.au
  7. Brown A, Carrington MJ, McGrady M, et al. Cardiometabolic risk and disease in Indigenous Australians: the heart of the heart study. Int J Cardiol 2014; 171(3):377-383. doi:10.1016/j.ijcard.2013.12.026
  8. Almeida OP, Flicker L, Fenner S, et al. The Kimberley assessment of depression of older Indigenous Australians: prevalence of depressive disorders, risk factors and validation of the KICA-dep scale. PLoS One 2014; 9(4):e94983. doi:10.1371/journal.pone.0094983
  9. Gee G, Dudgeon P, Schultz C, et al. Aboriginal and Torres Strait Islander social and emotional wellbeing. In: Dudgeon P, Milroy H, Walker R, editors. Working together: Aboriginal and Torres Strait Islander mental health and wellbeing principles and practice. 2nd ed. Canberra, Australia: Commonwealth of Australia; 2014.
  10. Le Grande M, Ski CF, Thompson DR, et al. Social and emotional wellbeing assessment instruments for use with Indigenous Australians: A critical review. Soc Sci Med 2017; 187:164-173. doi:10.1016/j.socscimed.2017.06.046
  11. Le Grande M, Jackson A, Ski C. Depression, cardiovascular disease and Indigenous Australians. In: Zangeneh M, Al-Krenawi A, editors. Culture, Diversity and Mental Health - Enhancing Clinical Practice. Cham, Switzerland: Springer Nature Switzerland; 2019. p. 167-184.
  12. Orringer CE, Blaha MJ, Blankstein R, et al. The National Lipid Association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction. J Clin Lipidol 2021; 15(1):33-60. doi:10.1016/j.jacl.2020.12.005
  13. Lin JS, Evans CV, Johnson E, et al. Nontraditional risk factors in cardiovascular disease risk assessment: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 2018; 320(3):281-297. doi:10.1001/jama.2018.4242 Guideline for assessing and managing cardiovascular disease risk Draft only, not implemented. March 2023. Not for publication until approved by Heart Foundation 109.
  14. Moon SJ, Chun EJ, Yoon YE, et al. Long-term prognostic value of coronary computed tomography angiography in an asymptomatic elderly population. J Am Heart Assoc 2019; 8(23):e013523. doi:10.1161/jaha.119.013523
  15. Mamudu HM, Paul TK, Veeranki SP, et al. The effects of coronary artery calcium screening on behavioral modification, risk perception, and medication adherence among asymptomatic adults: a systematic review. Atherosclerosis
    2014; 236(2):338-350. doi:10.1016/j.atherosclerosis.2014.07.022
  16. Gupta A, Lau E, Varshney R, et al. The identification of calcified coronary plaque is associated with initiation and continuation of pharmacological and lifestyle preventive therapies: a systematic review and meta-analysis. JACC Cardiovasc Imaging 2017; 10(8):833-842. doi:10.1016/j.jcmg.2017.01.030
  17. Min JK, Lin FY, Gidseg DS, et al. Determinants of coronary calcium conversion among patients with a normal coronary calcium scan: what is the "warranty period" for remaining normal? J Am Coll Cardiol
    2010; 55(11):1110-1117. doi:10.1016/j.jacc.2009.08.088
  18. Nasir K, Cainzos-Achirica M. Role of coronary artery calcium score in the primary prevention of cardiovascular disease. BMJ 2021; 373:n776. doi:10.1136/bmj.n776
  19. Sarwar A, Shaw LJ, Shapiro MD, et al. Diagnostic and prognostic value of absence of coronary artery calcification. JACC Cardiovasc Imaging 2009; 2(6):675-688. doi:10.1016/j.jcmg.2008.12.031
  20. Mortensen MB, Gaur S, Frimmer A, et al. Association of age with the diagnostic value of coronary artery calcium score for ruling out coronary stenosis in symptomatic patients. JAMA Cardiol 2021. doi:10.1001/jamacardio.2021.4406
  21. Fowkes FG, Murray GD, Butcher I, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA 2008; 300(2):197-208. doi:10.1001/jama.300.2.197
  22. Scott J, Lecouturier J, Rousseau N, et al. Nurses' and patients' experiences and preferences of the ankle-brachial pressure index and multi-site photoplethysmography for the diagnosis of peripheral arterial disease: A qualitative study. PLoS One 2019; 14(11):e0224546. doi:10.1371/journal.pone.0224546
  23. Ding T, Lloyd H. Perceptions of primary care and hospital clinicians on the use of the Ankle Brachial Pressure Index in general practice. J Prim Health Care 2021; 13(2):165-170. doi:10.1071/hc20057
  24. Luan YY, Yao YM. The clinical significance and potential role of C-reactive protein in chronic inflammatory and neurodegenerative diseases. Front Immunol 2018; 9:1302. doi:10.3389/fimmu.2018.01302
  25. Lawler PR, Bhatt DL, Godoy LC, et al. Targeting cardiovascular inflammation: next steps in clinical translation. Eur Heart J 2021; 42(1):113-131. doi:10.1093/eurheartj/ehaa099
  26. Urman A, Taklalsingh N, Sorrento C, et al. Inflammation beyond the joints: rheumatoid arthritis and cardiovascular disease. Scifed J Cardiol 2018; 2(3). doi:
  27. Pope JE, Choy EH. C-reactive protein and implications in rheumatoid arthritis and associated comorbidities. Semin Arthritis Rheum 2021; 51(1):219-229. doi:10.1016/j.semarthrit.2020.11.005
  28. Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 2017; 76(1):17-28. doi:10.1136/annrheumdis-2016-209775
  29. Hansildaar R, Vedder D, Baniaamam M, et al. Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout. Lancet Rheumatol 2021; 3(1):e58-e70. doi:10.1016/s2665-9913(20)30221-6
  30. Conrad N, Verbeke G, Molenberghs G, et al. Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. Lancet 2022; 400(10354):733-743. doi:10.1016/s0140-6736(22)01349-6
  31. Crowson CS, Gabriel SE, Semb AG, et al. Rheumatoid arthritis-specific cardiovascular risk scores are not superior to general risk scores: a validation analysis of patients from seven countries. Rheumatology (Oxford) 2017; 56(7):1102-1110. doi:10.1093/rheumatology/kex038
  32. Arnott C, Nelson M, Alfaro Ramirez M, et al. Maternal cardiovascular risk after hypertensive disorder of pregnancy. Heart 2020; 106(24):1927-1933. doi:10.1136/heartjnl-2020-316541
  33. Lo CCW, Lo ACQ, Leow SH, et al. Future cardiovascular disease risk for women with gestational hypertension: a systematic review and meta-analysis. J Am Heart Assoc 2020; 9(13):e013991. doi:10.1161/jaha.119.013991
  34. Brown MA, Magee LA, Kenny LC, et al. Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension 2018; 72(1):24-43. doi:10.1161/hypertensionaha.117.10803
  35. National Heart Foundation of Australia. Guideline for the diagnosis and management of hypertension in adults – 2016. Melbourne: National Heart Foundation of Australia; 2016. Available from: 
    heartfoundation.org.au
  36. Lowe S, Bowyer L, Lust K, et al. Guideline for the management of hypertensive disorders of pregnancy. Sydney: Society of Obstetric Medicine of Australia and New Zealand; 2014. Available from: https://ranzcog.edu.au/wp-cont...
  37. Department of Health. Clinical practice guidelines: pregnancy care. Canberra: Australian Government Department of Health; 2020. Available from:
    health.gov.au
  38. Poon LC, Shennan A, Hyett JA, et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet 2019; 145 Suppl 1(Suppl 1):1-33. doi:10.1002/ijgo.12802
  39. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; 42(34):3227-3337. doi:10.1093/eurheartj/ehab484
  40. Dall'Asta A, D'Antonio F, Saccone G, et al. Cardiovascular events following pregnancy complicated by pre-eclampsia with emphasis on comparison between early- and late-onset forms: systematic review and meta-analysis. Ultrasound Obstet Gynecol 2021; 57(5):698-709. doi:10.1002/uog.22107
  41. Brouwers L, van der Meiden-van Roest AJ, Savelkoul C, et al. Recurrence of pre-eclampsia and the risk of future hypertension and cardiovascular disease: a systematic review and meta-analysis. BJOG 2018; 125(13):1642-1654. doi:10.1111/1471-0528.15394
  42. Wu P, Haththotuwa R, Kwok CS, et al. Preeclampsia and future cardiovascular health: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes 2017; 10(2). doi:10.1161/circoutcomes.116.003497
  43. Theilen LH, Fraser A, Hollingshaus MS, et al. All-cause and cause-specific mortality after hypertensive disease of pregnancy. Obstet Gynecol 2016; 128(2):238-244. doi:10.1097/aog.0000000000001534
  44. Gunderson EP, Sun B, Catov JM, et al. Gestational diabetes history and glucose tolerance after pregnancy associated with coronary artery calcium in women during midlife: the CARDIA study. Circulation 2021; 143(10):974-987. doi:10.1161/circulationaha.120.047320
  45. Boyle DIR, Versace VL, Dunbar JA, et al. Results of the first recorded evaluation of a national gestational diabetes mellitus register: Challenges in screening, registration, and follow-up for diabetes risk. PLoS One 2018; 13(8):e0200832. doi:10.1371/journal.pone.0200832
  46. Nankervis A, McIntyre H, Moses R, et al. ADIPS consensus guidelines for the testing and diagnosis of hyperglycaemia in pregnancy in Australia and New Zealand (modified November 2014): Australasian Diabetes in Pregnancy Society; 2014. Available from:
    adips.org
  47. The Royal Australian College of General Practitioners. Management of type 2 diabetes: a handbook for general practice. East Melbourne: RACGP; 2020. Available from:
    racgp.org.au
  48. Australian Institute of Health and Welfare. Pregnancy and birth outcomes for Aboriginal and Torres Strait Islander women: 2016–2018. Canberra: AIHW; 2021. Available from:
    aihw.gov.au
  49. Ford EJ, Cade TJ, Doyle LW, et al. Pregnancy risk factors associated with birthweight of infants born to Australian Aboriginal women in an urban setting - a retrospective cohort study. BMC Pregnancy Childbirth 2018; 18(1):382. doi:10.1186/s12884-018-1946-3
  50. Daly AL, Sriram N, Woodall C, et al. Risk factors associated with hypertensive disorders of pregnancy within an urban indigenous population in south western Sydney. Intern Med J 2018; 48(3):269-275. doi:10.1111/imj.13669

100

  1. Hare MJL, Barzi F, Boyle JA, et al. Diabetes during pregnancy and birthweight trends among Aboriginal and non-Aboriginal people in the Northern Territory of Australia over 30 years. Lancet Reg Health West Pac 2020; 1:100005. doi:10.1016/j.lanwpc.2020.100005
  2. Chamberlain C, Joshy G, Li H, et al. The prevalence of gestational diabetes mellitus among Aboriginal and Torres Strait Islander women in Australia: a systematic review and meta-analysis. Diabetes Metab Res Rev 2015; 31(3):234-247. doi:10.1002/dmrr.2570
  3. Honigberg MC, Zekavat SM, Aragam K, et al. Association of premature natural and surgical menopause with incident cardiovascular disease. JAMA 2019; 322(24):2411-2421. doi:10.1001/jama.2019.19191
  4. Zhu D, Chung HF, Dobson AJ, et al. Type of menopause, age of menopause and variations in the risk of incident cardiovascular disease: pooled analysis of individual data from 10 international studies. Hum Reprod 2020; 35(8):1933-1943. doi:10.1093/humrep/deaa124
  5. Zhu D, Chung HF, Dobson AJ, et al. Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data. Lancet Public Health 2019; 4(11):e553-e564. doi:10.1016/s2468-2667(19)30155-0
  6. Appiah D, Schreiner PJ, Demerath EW, et al. Association of age at menopause with incident heart failure: a prospective cohort study and meta-analysis. J Am Heart Assoc 2016; 5(8). doi:10.1161/jaha.116.003769
  7. Muka T, Oliver-Williams C, Kunutsor S, et al. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis. JAMA Cardiol 2016; 1(7):767-776. doi:10.1001/jamacardio.2016.2415
  8. Ley SH, Li Y, Tobias DK, et al. Duration of reproductive life span, age at menarche, and age at menopause are associated with risk of cardiovascular disease in women. J Am Heart Assoc 2017; 6(11). doi:10.1161/jaha.117.006713
  9. Magraith K, Stuckey B. Making choices at menopause. Aust J Gen Pract 2019; 48(7):457-462. doi:10.31128/ajgp-02-19-4851
  10. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41(1):111-188. doi:10.1093/eurheartj/ehz455
  11. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 139(25):e1046-e1081. doi:10.1161/cir.0000000000000624
  12. Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302(18):1993-2000. doi:10.1001/jama.2009.1619
  13. Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet 2014; 384(9943):626-635. doi:10.1016/s0140-6736(14)61177-6
  14. Welsh C, Celis-Morales CA, Brown R, et al. Comparison of conventional lipoprotein tests and apolipoproteins in the prediction of cardiovascular disease. Circulation 2019; 140(7):542-552. doi:10.1161/circulationaha.119.041149
  15. Langlois MR, Chapman MJ, Cobbaert C, et al. Quantifying atherogenic lipoproteins: current and future challenges in the era of personalized medicine and very low concentrations of LDL cholesterol. A consensus statement from EAS and EFLM. Clin Chem 2018; 64(7):1006-1033. doi:10.1373/clinchem.2018.287037
  16. Johannesen CDL, Mortensen MB, Langsted A, et al. Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients. J Am Coll Cardiol 2021; 77(11):1439-1450. doi:10.1016/j.jacc.2021.01.027
  17. Alonso R, Andres E, Mata N, et al. Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. J Am Coll Cardiol 2014; 63(19):1982-1989. doi:10.1016/j.jacc.2014.01.063
  18. Ellis KL, Pérez de Isla L, Alonso R, et al. Value of measuring lipoprotein(a) during cascade testing for familial hypercholesterolemia. J Am Coll Cardiol 2019; 73(9):1029-1039. doi:10.1016/j.jacc.2018.12.037
  19. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010; 31(23):2844-2853. doi:10.1093/eurheartj/ehq386
  20. Wilson DP, Jacobson TA, Jones PH, et al. Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol 2019; 13(3):374-392. doi:10.1016/j.jacl.2019.04.010
  21. Rao AS, Knowles JW. Polygenic risk scores in coronary artery disease. Curr Opin Cardiol 2019; 34(4):435-440. doi:10.1097/HCO.0000000000000629
  22. Vernon ST, Coffey S, Bhindi R, et al. Increasing proportion of ST elevation myocardial infarction patients with coronary atherosclerosis poorly explained by standard modifiable risk factors. Eur J Prev Cardiol 2017; 24(17):1824-1830. doi:10.1177/2047487317720287
  23. Vernon ST, Coffey S, D'Souza M, et al. ST-segment-elevation myocardial infarction (STEMI) patients without standard modifiable cardiovascular risk factors – how common are they, and what are their outcomes? J Am Heart Assoc 2019; 8(21):e013296. doi:10.1161/JAHA.119.013296
  24. Figtree GA, S.T. V, Hadziosmanovic N, et al. Mortality in STEMI patients without standard modifiable risk factors: a sex disaggregated analysis from the SWEDEHEART registry. . The Lancet 2021; S0140-6736(21):272-275. doi:
  25. Assimes TL, Salfati EL, Del Gobbo LC. Leveraging information from genetic risk scores of coronary atherosclerosis. Curr Opin Lipidol 2017; 28(2):104-112. doi:10.1097/MOL.0000000000000400
  26. Inouye M, Abraham G, Nelson CP, et al. Genomic risk prediction of coronary artery disease in 480,000 adults: implications for primary prevention. J Am Coll Cardiol 2018; 72(16):1883-1893. doi:10.1016/j.jacc.2018.07.079
  27. Khera AV, Chaffin M, Aragam KG, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet 2018; 50(9):1219-1224. doi:10.1038/s41588-018-0183-z
  28. Damask A, Steg PG, Schwartz GG, et al. Patients with high genome-wide polygenic risk scores for coronary artery disease may receive greater clinical benefit from alirocumab treatment in the ODYSSEY OUTCOMES trial. Circulation 2020; 141(8):624-636. doi:10.1161/CIRCULATIONAHA.119.044434
  29. Mega JL, Stitziel NO, Smith JG, et al. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet 2015; 385(9984):2264-2271. doi:10.1016/S0140-6736(14)61730-X
  30. Tada H, Melander O, Louie JZ, et al. Risk prediction by genetic risk scores for coronary heart disease is independent of self-reported family history. Eur Heart J 2016; 37(6):561-567. doi:10.1093/eurheartj/ehv462
  31. Abraham G, Havulinna AS, Bhalala OG, et al. Genomic prediction of coronary heart disease. Eur Heart J 2016; 37(43):3267-3278. doi:10.1093/eurheartj/ehw450
  32. Bolli A, Di Domenico P, Botta G. Software as a service for the genomic prediction of complex diseases. bioRxiv 2019; doi.org/10.1101/763722.
  33. Zaman S, MacIsaac AI, Jennings GL, et al. Cardiovascular disease and COVID-19: Australian and New Zealand consensus statement. Med J Aust 2020; 213(4):182-187. doi:10.5694/mja2.50714
  34. Xie Y, Xu E, Bowe B, et al. Long-term cardiovascular outcomes of COVID-19. Nat Med 2022; 28(3):583-590. doi:10.1038/s41591-022-01689-3
  35. Bonner C, Trevena LJ, Gaissmaier W, et al. Current best practice for presenting probabilities in patient decision aids: fundamental principles. Med Decis Making 2021; 41(7):821-833. doi:10.1177/0272989x21996328
  36. Trevena LJ, Bonner C, Okan Y, et al. Current challenges when using numbers in patient decision aids: advanced concepts. Med Decis Making 2021; 41(7):834-847. doi:10.1177/0272989x21996342
  37. Deshmukh T, Abbott P, Reath J. 'It's got to be another approach': an Aboriginal health worker perspective on cardiovascular risk screening and education. Aust Fam Physician 2014; 43(7):475-478.
  38. Brown A, O'Shea RL, Mott K, et al. Essential service standards for equitable national cardiovascular care for Aboriginal and Torres Strait Islander people. Heart Lung Circ 2015; 24(2):126-141. doi:10.1016/j.hlc.2014.09.021
  39. Aspin C, Brown N, Jowsey T, et al. Strategic approaches to enhanced health service delivery for Aboriginal and Torres Strait Islander people with chronic illness: a qualitative study. BMC Health Serv Res 2012; 12:143. doi:10.1186/1472-6963-12-143
  40. McBride KF, Franks C, Wade V, et al. Good Heart: telling stories of cardiovascular protective and risk factors for Aboriginal women. Heart Lung Circ 2021; 30(1):69-77. doi:10.1016/j.hlc.2020.09.931
  41. Reilly RE, Doyle J, Bretherton D, et al. Identifying psychosocial mediators of health amongst Indigenous Australians for the Heart Health Project. Ethn Health 2008; 13(4):351-373. doi:10.1080/13557850801903046
  42. Artuso S, Cargo M, Brown A, et al. Factors influencing health care utilisation among Aboriginal cardiac patients in central Australia: a qualitative study. BMC Health Serv Res 2013; 13:83. doi:10.1186/1472-6963-13-83
  43. Eades A, Hackett ML, Liu H, et al. Qualitative study of psychosocial factors impacting on Aboriginal women's management of chronic disease. Int J Equity Health 2020; 19(1):8. doi:10.1186/s12939-019-1110-3
  44. Institute for Evidence-based Care – Bond University. Evidence synthesis to support the development of guidelines for absolute cardiovascular disease risk: Prepared for the National Heart Foundation; 2021.
  45. Bonner C, Batcup C, Cornell S, et al. Interventions using Heart Age for cardiovascular disease risk communication: systematic review of psychological, behavioral, and clinical effects. JMIR Cardio 2021; 5(2):e31056. doi:10.2196/31056
  46. Stacey D, Légaré F, Lewis K, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2017; 4:CD001431. doi:10.1002/14651858.CD001431.pub5
  47. Dailey G. Overall mortality in diabetes mellitus: where do we stand today? Diabetes Technol Ther 2011; 13 Suppl 1:S65-74. doi:10.1089/dia.2011.0019
  48. Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020; 383(15):1413-1424. doi:10.1056/NEJMoa2022190
  49. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019; 381(21):1995-2008. doi:10.1056/NEJMoa1911303
  50. Ferro EG, Michos ED, Bhatt DL, et al. New decade, new FDA guidance for diabetes drug development: lessons learned and future directions. J Am Coll Cardiol 2020; 76(21):2522-2526. doi:10.1016/j.jacc.2020.09.590

150

  1. National Heart Foundation of Australia. Position statement: Smoking and vaping cessation. Heart Foundation; 2021. Available from:
    heartfoundation.org.au
  2. Australian Institute of Health and Welfare. Australian Burden of Disease Study 2018: key findings. Australian Burden of Disease Study series 24. Cat. no. BOD 30. Canberra: AIHW; 2021. Available from:
    aihw.gov.au
  3. Royal Australian College of General Practitioners. Supporting smoking cessation: A guide for health professionals. Last revised 29 Sep 2021: RACGP; 2021. Available from:
    racgp.org.au
  4. Australian Institute of Health and Welfare. Aboriginal and Torres Strait Islander Health Performance Framework 2020: detailed analysis. Cat. no. IHW 94. Canberra: AIHW; 2020. Available from:
    indigenoushpf.gov.au
  5. Greenhalgh E, Maddox R, van der Sterren AK, D Winstanley, MH. Prevalence of tobacco use among Aboriginal and Torres Strait Islander peoples. In: Greenhalgh E, Scollo M, Winstanley M, editors. Tobacco in Australia. Melbourne: Cancer Council Victoria; 2022. Available from:
    tobaccoinaustralia.org.au
  6. Cahill K, Lindson-Hawley N, Thomas KH, et al. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2016; 5:CD006103. doi:10.1002/14651858.CD006103.pub7
  7. Hartmann-Boyce J, Chepkin SC, Ye W, et al. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev 2018; 5:CD000146. doi:10.1002/14651858.CD000146.pub5
  8. Lindson N, Chepkin SC, Ye W, et al. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2019; 4:CD013308. doi:10.1002/14651858.Cd013308
  9. Howes S, Hartmann-Boyce J, Livingstone-Banks J, et al. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2020; 4:CD000031. doi:10.1002/14651858.CD000031.pub5
  10. Mozaffarian D. Dietary and policy priorities for cardiovascular disease, diabetes, and obesity: a comprehensive review. Circulation 2016; 133(2):187-225. doi:10.1161/circulationaha.115.018585
  11. Heart Foundation. Healthy eating to protect your heart. 2021 [updated 2021; cited 2021 October]; Web page]. Available from:
    heartfoundation.org.au
  12. Heart Foundation. Dietary position statement. Heart healthy eating patterns: National Heart Foundation of Australia; 2019. Available from:
    heartfoundation.org.au
  13. Collins C, Burrows T, Rollo M. Dietary Patterns and Cardiovascular Disease Outcomes: an Evidence Check rapid review brokered by the Sax Institute (
    www.saxinstitute.org.au) for the National Heart Foundation of Australia: Sax Institute; 2017. Available from:
    saxinstitute.org.au
  14. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997; 336(16):1117-1124. doi:10.1056/nejm199704173361601
  15. World Health Organization. The Global Health Observatory Indicator Medadata Registry List: Salt intake. [Web page]: WHO; [cited 2022]; Available from:
    who.int
  16. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001; 344(1):3-10. doi:10.1056/nejm200101043440101
  17. Rees K, Takeda A, Martin N, et al. Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2019; 3(3):CD009825. doi:10.1002/14651858.CD009825.pub3
  18. National Health and Medical Research Council. Australian dietary guidelines. Canberra: National Health and Medical Research Council; 2013.
  19. National Heart Foundation. Fish, seafood and heart healthy eating. Dietary position statement: National Heart Foundation; 2015. Available from:
    heartfoundation.org.au
  20. Bernasconi AA, Wiest MM, Lavie CJ, et al. Effect of omega-3 dosage on cardiovascular outcomes: an updated meta-analysis and meta-regression of interventional trials. Mayo Clin Proc 2021; 96(2):304-313. doi:10.1016/j.mayocp.2020.08.034
  21. Khan SU, Lone AN, Khan MS, et al. Effect of omega-3 fatty acids on cardiovascular outcomes: a systematic review and meta-analysis. EClinicalMedicine 2021; 38:100997. doi:10.1016/j.eclinm.2021.100997
  22. Abdelhamid AS, Brown TJ, Brainard JS, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2020; 3(3):CD003177. doi:10.1002/14651858.CD003177.pub5
  23. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 2019; 380(1):11-22. doi:10.1056/NEJMoa1812792
  24. Giosuè A, Calabrese I, Lupoli R, et al. Relations between the consumption of fatty or lean fish and risk of cardiovascular disease and all-cause mortality: a systematic review and meta-analysis. Adv Nutr 2022. doi:10.1093/advances/nmac006
  25. Livingstone KM, Milte CM, Torres SJ, et al. Nineteen-year associations between three diet quality indices and all-cause and cardiovascular disease mortality: The Australian Diabetes, Obesity, and Lifestyle Study. J Nutr 2022; 152(3):805-815. doi:10.1093/jn/nxab386
  26. Schulze MB, Martínez-González MA, Fung TT, et al. Food based dietary patterns and chronic disease prevention. BMJ 2018; 361:k2396. doi:10.1136/bmj.k2396
  27. George ES, Kucianski T, Mayr HL, et al. A Mediterranean diet model in Australia: strategies for translating the traditional Mediterranean diet into a multicultural setting. Nutrients 2018; 10(4). doi:10.3390/nu10040465
  28. Springmann M, Clark MA, Rayner M, et al. The global and regional costs of healthy and sustainable dietary patterns: a modelling study. Lancet Planet Health 2021; 5(11):e797-e807. doi:10.1016/s2542-5196(21)00251-5
  29. Rohit A, Brimblecombe J, O'Dea K, et al. Development of a short-item diet quality questionnaire for Indigenous mothers and their young children: The Menzies remote short-item dietary assessment tool. Aust J Rural Health 2018; 26(3):220-224. doi:10.1111/ajr.12412
  30. Tonkin E, Kennedy D, Golley R, et al. The relative validity of the Menzies Remote Short-Item Dietary Assessment Tool (MRSDAT) in Aboriginal Australian children Aged 6-36 months. Nutrients 2018; 10(5). doi:10.3390/nu10050590
  31. Porykali B, Davies A, Brooks C, et al. Effects of nutritional interventions on cardiovascular disease health outcomes in Aboriginal and Torres Strait Islander Australians: a scoping review. Nutrients 2021; 13(11). doi:10.3390/nu13114084
  32. Jayedi A, Soltani S, Abdolshahi A, et al. Healthy and unhealthy dietary patterns and the risk of chronic disease: an umbrella review of meta-analyses of prospective cohort studies. Br J Nutr 2020; 124(11):1133-1144. doi:10.1017/s0007114520002330
  33. Hajjar M, Rezazadeh A. The Recommended Food Score and Healthy Nordic Food Index in cardiovascular disease and stroke: A systematic review. ARYA Atheroscler 2020; 16(5):248-257. doi:10.22122/arya.v16i5.2067
  34. Filippou CD, Tsioufis CP, Thomopoulos CG, et al. Dietary Approaches to Stop Hypertension (DASH) Diet and blood pressure reduction in adults with and without hypertension: a systematic review and meta-analysis of randomized controlled trials. Adv Nutr 2020; 11(5):1150-1160. doi:10.1093/advances/nmaa041
  35. Adler AJ, Taylor F, Martin N, et al. Reduced dietary salt for the prevention of cardiovascular disease. Cochrane Database Syst Rev 2014; 2014(12):CD009217. doi:10.1002/14651858.CD009217.pub3
  36. Jennings G, Nelson L, Nestel P, et al. The effects of changes in physical activity on major cardiovascular risk factors, hemodynamics, sympathetic function, and glucose utilization in man: a controlled study of four levels of activity. Circulation 1986; 73(1):30-40. doi:10.1161/01.cir.73.1.30
  37. Ekelund U, Tarp J, Steene-Johannessen J, et al. Dose-response associations between accelerometry measured physical activity and sedentary time and all cause mortality: systematic review and harmonised meta-analysis. BMJ 2019; 366:l4570. doi:10.1136/bmj.l4570
  38. Biswas A, Oh PI, Faulkner GE, et al. Sedentary time and its association with risk for disease incidence, mortality, and hospitalization in adults: a systematic review and meta-analysis. Ann Intern Med 2015; 162(2):123-132. doi:10.7326/m14-1651
  39. Pescatello LS, Buchner DM, Jakicic JM, et al. Physical activity to prevent and treat hypertension: a systematic review. Med Sci Sports Exerc 2019; 51(6):1314-1323. doi:10.1249/mss.0000000000001943
  40. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42(6):1206-1252. doi:10.1161/01.HYP.0000107251.49515.c2
  41. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338:b1665. doi:10.1136/bmj.b1665
  42. Whelton PK, He J, Appel LJ, et al. Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. JAMA 2002; 288(15):1882-1888. doi:10.1001/jama.288.15.1882
  43. World Health Organization. WHO guidelines on physical activity and sedentary behaviour. Geneva: WHO; 2020. Available from:
    who.int
  44. Abell B, Glasziou P, Hoffmann T. The contribution of individual exercise training components to clinical outcomes in randomised controlled trials of cardiac rehabilitation: a systematic review and meta-regression. Sports Med Open 2017; 3(1):19. doi:10.1186/s40798-017-0086-z
  45. The Royal Australian College of General Practitioners. Smoking, nutrition, alcohol and physical activity (SNAP). A population health guide to behavioural risk factors in general practice. 2nd ed. Melbourne: RACGP; 2015. Available from:
    racgp.org.au
  46. Sushames A, van Uffelen JG, Gebel K. Do physical activity interventions in Indigenous people in Australia and New Zealand improve activity levels and health outcomes? A systematic review. Int J Behav Nutr Phys Act 2016; 13(1):129. doi:10.1186/s12966-016-0455-x
  47. Semlitsch T, Krenn C, Jeitler K, et al. Long-term effects of weight-reducing diets in people with hypertension. Cochrane Database Syst Rev 2021; 2(2):CD008274. doi:10.1002/14651858.CD008274.pub4
  48. Hasan B, Nayfeh T, Alzuabi M, et al. Weight loss and serum lipids in overweight and obese adults: a systematic review and meta-analysis. J Clin Endocrinol Metab 2020; 105(12). doi:10.1210/clinem/dgaa673
  49. Semlitsch T, Stigler FL, Jeitler K, et al. Management of overweight and obesity in primary care – A systematic overview of international evidence-based guidelines. Obes Rev 2019; 20(9):1218-1230. doi:10.1111/obr.12889
  50. Piers LS, Rowley KG, Soares MJ, et al. Relation of adiposity and body fat distribution to body mass index in Australians of Aboriginal and European ancestry. Eur J Clin Nutr 2003; 57(8):956-963. doi:10.1038/sj.ejcn.1601630

200

  1. Kondalsamy-Chennakesavan S, Hoy WE, Wang Z, et al. Anthropometric measurements of Australian Aboriginal adults living in remote areas: comparison with nationally representative findings. Am J Hum Biol 2008; 20(3):317-324. doi:10.1002/ajhb.20729
  2. Adegbija O, Hoy WE, Wang Z. Waist circumference values equivalent to body mass index points for predicting absolute cardiovascular disease risks among adults in an Aboriginal community: a prospective cohort study. BMJ Open 2015; 5(11):e009185. doi:10.1136/bmjopen-2015-009185
  3. Wang Z, Hoy WE. Waist circumference, body mass index, hip circumference and waist-to-hip ratio as predictors of cardiovascular disease in Aboriginal people. Eur J Clin Nutr 2004; 58(6):888-893. doi:10.1038/sj.ejcn.1601891
  4. Adegbija O, Hoy W, Wang Z. Prediction of cardiovascular disease risk using waist circumference among Aboriginals in a remote Australian community. BMC Public Health 2015; 15:57. doi:10.1186/s12889-015-1406-1
  5. World Health Organization. Obesity: preventing and managing the global epidemic. Geneva: WHO; 1997.
  6. Bohn-Goldbaum E, Cashmore A, Fonua R, et al. Weight change among repeat participants of an Aboriginal community-based weight loss program. BMC Public Health 2020; 20(1):1003. doi:10.1186/s12889-020-09086-6
  7. Passmore E, Shepherd B, Milat A, et al. The impact of a community-led program promoting weight loss and healthy living in Aboriginal communities: the New South Wales Knockout Health Challenge. BMC Public Health 2017; 17(1):951. doi:10.1186/s12889-017-4955-7
  8. Ma C, Avenell A, Bolland M, et al. Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis. BMJ 2017; 359:j4849. doi:10.1136/bmj.j4849
  9. National Heart Foundation of Australia. Position statement. Alcohol and heart health. Heart Foundation; 2021. Available from:
    heartfoundation.org.au
  10. NHMRC Clinical Trials Centre The University of Sydney. Evaluating the evidence on the health effects of alcohol consumption. Evidence evaluation report: NHMRC; 2020. Available from:
    nhmrc.gov.au
  11. Roerecke M, Kaczorowski J, Tobe SW, et al. The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis. Lancet Public Health 2017; 2(2):e108-e120. doi:10.1016/s2468-2667(17)30003-8
  12. National Health and Medical Research Council, Australian Research Council, Universities Australia. Australian guidelines to reduce health risks from drinking alcohol. Canberra: Commonwealth of Australia; 2020. Available from:
    nhmrc.gov.au
  13. Australian Government Department of Health and Aged Care. Standard drinks guide. Australian Government Department of Health and Aged Care; 2020 [updated 8 December 2020; cited 2022 August]; Available from:
    health.gov.au
  14. Australian Institute of Health and Welfare. Aboriginal and Torres Strait Islander Health Performance Framework 2012: detail analysis. Cat. no. IHW 94. Canberra: AIHW; 2013. Available from:
    aihw.gov.au
  15. Gray D, Saggers S, Atkinson D, et al. Substance misuse and primary health care among Indigenous Australians. Aboriginal and Torres Strait Islander Primary Health Care Review: Consultant Report No 7: Australian Government; 2004.
  16. Lee K, Freeburn B, Ella S, et al. Handbook for Aboriginal alcohol and drug work. Sydney: University of Sydney; 2012.
  17. Nazarzadeh M, Bidel Z, Canoy D, et al. Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis. Lancet 2021; 398(10313):1803-1810. doi:10.1016/s0140-6736(21)01920-6
  18. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375(9716):735-742. doi:10.1016/s0140-6736(09)61965-6
  19. Cholesterol Treatment Trialists' (CTT) Collaboration. Protocol for analyses of adverse event data from randomized controlled trials of statin therapy. Am Heart J 2016; 176:63-69. doi:10.1016/j.ahj.2016.01.016
  20. Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet 2019; 393(10170):407-415. doi:10.1016/s0140-6736(18)31942-1
  21. The Blood Pressure Lowering Treatment Trialists' Collaboration. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. Lancet 2021; 398(10305):1053-1064. doi:10.1016/s0140-6736(21)01921-8
  22. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 2016; 387(10017):435-443. doi:10.1016/s0140-6736(15)00805-3
  23. Blood Pressure Lowering Treatment Trialists' Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet 2021; 397(10285):1625-1636. doi:10.1016/s0140-6736(21)00590-0
  24. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015; 385(9976):1397-1405. doi:10.1016/s0140-6736(14)61368-4
  25. Familial Hypercholesterolaemia Australasia Network. How to manage FH. [Web page]: FH Australasia Network; 2021 [cited 2021 November]; Available from:
    athero.org.au
  26. The Royal Australian College of General Practitioners. Guidelines for preventive activities in general practice. 9th edn. East Melbourne: RACGP; 2018.
  27. Bytyçi I, Penson PE, Mikhailidis DP, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J 2022. doi:10.1093/eurheartj/ehac015
  28. O'Neal DN, Piers LS, Iser DM, et al. Australian Aboriginal people and Torres Strait Islanders have an atherogenic lipid profile that is characterised by low HDL-cholesterol level and small LDL particles. Atherosclerosis 2008; 201(2):368-377. doi:10.1016/j.atherosclerosis.2008.03.022
  29. Khan SU, Khan MU, Virani SS, et al. Efficacy and safety for the achievement of guideline-recommended lower low-density lipoprotein cholesterol levels: a systematic review and meta-analysis. Eur J Prev Cardiol 2020. doi:10.1093/eurjpc/zwaa093
  30. Joseph P, Roshandel G, Gao P, et al. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet 2021; 398(10306):1133-1146. doi:10.1016/s0140-6736(21)01827-4
  31. Baumgartner A, Drame K, Geutjens S, et al. Does the polypill improve patient adherence compared to its individual formulations? A systematic review. Pharmaceutics 2020; 12(2). doi:10.3390/pharmaceutics12020190
  32. Parati G, Kjeldsen S, Coca A, et al. Adherence to single-pill versus free-equivalent combination therapy in hypertension: a systematic review and meta-Analysis. Hypertension 2021; 77(2):692-705. doi:10.1161/hypertensionaha.120.15781